These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15023243)

  • 1. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
    Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
    Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
    Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
    Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
    Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
    Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
    Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
    Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
    Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.
    Sato N; Sano M; Tabei T; Asaga T; Ando J; Fujii H; Yamamoto N; Kurosumi M; Inoue K; Kimura M
    Breast Cancer; 2006; 13(2):166-71. PubMed ID: 16755112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
    Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
    Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.
    Zhao M; Pan X; Layman R; Lustberg MB; Mrozek E; Macrae ER; Wesolowski R; Carothers S; Puhalla S; Shapiro CL; Ramaswamy B
    Invest New Drugs; 2014 Dec; 32(6):1285-94. PubMed ID: 24894652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.
    Van Pelt AE; Mohsin S; Elledge RM; Hilsenbeck SG; Gutierrez MC; Lucci A; Kalidas M; Granchi T; Scott BG; Allred DC; Chang JC
    Clin Breast Cancer; 2003 Dec; 4(5):348-53. PubMed ID: 14715110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
    Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
    Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
    Pegram MD; O'Callaghan C
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S15-9. PubMed ID: 11970740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.